Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Mesothelioma, Malignant 2Colorectal Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma, Synovial 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Liposarcoma, Myxoid 1Kidney Neoplasms 1Infections 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Trabectedin 3Radiation Dose Hypofractionation 3Cyclophosphamide 3fludarabine 2ribociclib 1pembrolizumab 1interferon gamma-1b 1cytochrome C synthetase 1brostallicin 1atezolizumab 1Sirolimus 1Pioglitazone 1Interferon-gamma 1Diathermy 1Dexamethasone 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma, Myxoid × Interferon-gamma × Clear all
NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡